Aflibercept plus FOLFIRI for 2nd line treatment of metastatic colorectal cancer (mCRC): Long-term safety observation from the global aflibercept safety and quality-of-life (QoL) program (ASQoP)

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search DSpace


My Account